NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癌症診斷市場成長機會·成長預測 (2021-2028年):產品·用途·終端用戶產業·各地區

Cancer Diagnostics Market by Product, Application, and End Use : Opportunity Analysis and Industry Forecast, 2021-2028

出版商 Allied Market Research 商品編碼 1017289
出版日期 內容資訊 英文 239 Pages
商品交期: 2-3個工作天內
價格
癌症診斷市場成長機會·成長預測 (2021-2028年):產品·用途·終端用戶產業·各地區 Cancer Diagnostics Market by Product, Application, and End Use : Opportunity Analysis and Industry Forecast, 2021-2028
出版日期: 2021年05月28日內容資訊: 英文 239 Pages
簡介

癌症診斷的市場規模在預測期間內預計將以6.9%的年複合成長率推移,從2020年的1686億4萬美元,成長到2028年2805億9021萬美元的規模。

政府和其他私營組織加強對癌症早期診斷和預防的提高認識活動,發達國家的診斷實驗室數量增加,各種癌症(如乳腺癌和肺癌)的發病率和患病率增加等因素正在推動市場的增長。但另一方面,診斷成像系統的高成本和各種癌症突變診斷方法的開發等因素可能會阻礙市場的進一步增長。

本報告提供全球癌症診斷的市場調查,彙整市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,市場規模的轉變·預測,產品·用途·終端用戶·地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義·範圍
  • 主要調查結果
  • 波特的五力分析
  • 主要企業的地位
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • COVID-19:影響分析

第4章 市場分析·預測:各產品

  • 主要趨勢·成長要素·成長機會
  • 市場規模·預測:各地區
  • 市場分析:各國
  • 市場規模·預測
  • 消耗品
    • 抗體
    • 套件·試劑
    • 探針
    • 其他
  • 設備
    • 病理為基礎的
    • 影像設備
    • 切片檢查器具

第5章 市場分析·預測:各用途

  • 乳癌
  • 大腸癌
  • 子宮頸癌
  • 肺癌
  • 前列腺癌
  • 皮膚癌
  • 血液癌症
  • 腎臟癌
  • 肝癌
  • 胰臟癌
  • 卵巢癌
  • 其他

第6章 市場分析·預測:各終端用戶

  • 醫院·診所
  • 診斷實驗室
  • 影像診斷中心
  • 研究機關
    • 市場規模·預測:各地區
    • 市場分析:各國

第7章 市場分析·預測:地區·各主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲
    • 主要趨勢·成長要素·成長機會
    • 市場規模·預測:各國
    • 市場規模·預測:各產品
    • 市場規模·預測:各用途
    • 市場規模·預測:各終端用戶

第8章 企業簡介

  • ABBOTT LABORATORIES
  • BECTON, DICKINSON AND COMPANY
  • Bio-Rad Laboratories, Inc.
  • Roche Holdings AG(F. Hoffmann-La Roche Ltd.)
  • Danaher Corporation(GE Healthcare)
  • Hologic, Inc.
  • KONINKLIJKE PHILIPS N.V.(Philips Healthcare)
  • Qiagen N.V.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific
目錄
Product Code: A11336

The cancer diagnostics market was valued at $168,600.04 million in 2020, and is projected to reach $280,590.21 million by 2028, registering a CAGR of 6.9% from 2021 to 2028.

Cancer diagnostics is the process of detecting biomarkers, proteins, and other indicators that contribute to the detection of a cancerous tumor. Effective diagnostic testing is used to confirm or rule out the presence of infection, monitor disease severity, and plan & evaluate clinical outcomes. Diagnostic procedures for cancer may include imaging, laboratory tests (including tests for tumor markers), endoscopic examination, tumor biopsy, surgery, or genetic testing.

The major factor that contributes to the growth of the cancer diagnostics market includes surge in government initiatives and other private organizations to spread awareness regarding early diagnosis and prevention of cancer, which is anticipated to boost the growth of the market in the coming years. Furthermore, the growth in the number of diagnostics laboratories in developed countries is expected to drive the market growth in the next few years. Increase in incidences and prevalence of various types of cancer, such as breast cancer and lung cancer, are expected to drive the growth of the market.

However, huge cost associated with diagnostic imaging system and development of different diagnostic approaches for various cancer mutations may hinder the growth of the market. Conversely, increase in emphasis over health & safety regulations and surge in popularity of yoga and other health related practices will act as a growth opportunity during the forecast period.

The cancer diagnostics market is segmented on the basis of basis of product, application, and end use to provide a detailed assessment of the market. By product, the market is bifurcated into consumables and instruments. Further, consumables are divided into antibodies, kits & reagents, probes, and other consumables. Instruments include pathology-based instruments, imaging instruments, and biopsy instruments. On the basis of application, the market is fragmented into breast cancer, lung cancer, blood cancer, colorectal cancer, skin cancer, ovarian cancer, prostate cancer, kidney cancer, liver cancer, pancreatic cancer, cervical cancer, and others. Based on end use, the market is classified into hospitals & clinics, diagnostic laboratories, diagnostic imaging centers, and research institutes. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2020 to 2028, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of factors that drive and restrain the growth of the market is provided.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Product

  • Consumables
  • Antibodies
  • Kits & Reagents
  • Probes
  • Other consumables
  • Instruments
  • Pathology-based Instruments
  • Imaging Instruments
  • Biopsy Instruments

By Application

  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

By End Use

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Research Institutes
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Roche Holdings AG (F. Hoffmann-La Roche Ltd.)
  • Danaher Corporation (GE Healthcare)
  • Hologic, Inc.
  • Koninklijke Philips N.V. (Philips Healthcare)
  • Qiagen N.V.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key Benefits for Stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
    • 3.3.1.Bargaining power of buyers
    • 3.3.2.Bargaining power of suppliers
    • 3.3.3.Thereat of new entrants
    • 3.3.4.Threat of substitutes
    • 3.3.5.Intensity of competitive rivalry
  • 3.4.Top player positioning, 2019
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Rise in incidences and prevalence of various cancer types
      • 3.5.1.2.Increase in technological advancements
      • 3.5.1.3.Government initiatives and other organization to spread awareness about cancer
      • 3.5.1.4.Growing number of diagnostics laboratories In developed countries
    • 3.5.2.Restraints
      • 3.5.2.1.Huge cost associated with diagnostic imaging system
      • 3.5.2.2.Risk related with high radiation exposure affecting use of CT scanner
    • 3.5.3.Opportunities
      • 3.5.3.1.Development of diagnostic approaches for various cancer mutation
  • 3.6.Impact Analysis
  • 3.7.Impact Analysis of the Covid-19 on Cancer Diagnostics Market

CHAPTER 4:CANCER DIAGNOSTICS MARKET, BY PRODUCT

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Consumables
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
    • 4.2.4.Market size and forecast, by type
    • 4.2.5.Antibodies
      • 4.2.5.1.Market size and forecast
    • 4.2.6.Kits & Reagents
      • 4.2.6.1.Market size and forecast
    • 4.2.7.Probes
      • 4.2.7.1.Market size and forecast
    • 4.2.8.Other consumables
      • 4.2.8.1.Market size and forecast
  • 4.3.Instruments
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
    • 4.3.4.Market size and forecast, by type
    • 4.3.5.Pathology-based Instruments
      • 4.3.5.1.Market size and forecast
    • 4.3.6.Imaging Instruments
      • 4.3.6.1.Market size and forecast
    • 4.3.7.Biopsy Instruments
      • 4.3.7.1.Market size and forecast

CHAPTER 5:CANCER DIAGNOSTICS MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Breast Cancer
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Colorectal Cancer
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Cervical Cancer
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country
  • 5.5.Lung Cancer
    • 5.5.1.Market size and forecast, by region
    • 5.5.2.Market analysis, by country
  • 5.6.Prostate Cancer
    • 5.6.1.Market size and forecast, by region
    • 5.6.2.Market analysis, by country
  • 5.7.Skin Cancer
    • 5.7.1.Market size and forecast, by region
    • 5.7.2.Market analysis, by country
  • 5.8.Blood Cancer
    • 5.8.1.Market size and forecast, by region
    • 5.8.2.Market analysis, by country
  • 5.9.Kidney Cancer
    • 5.9.1.Market size and forecast, by region
    • 5.9.2.Market analysis, by country
  • 5.10.Liver Cancer
    • 5.10.1.Market size and forecast, by region
    • 5.10.2.Market analysis, by country
  • 5.11.Pancreatic Cancer
    • 5.11.1.Market size and forecast, by region
    • 5.11.2.Market analysis, by country
  • 5.12.Ovarian Cancer
    • 5.12.1.Market size and forecast, by region
    • 5.12.2.Market analysis, by country
  • 5.13.Others
    • 5.13.1.Market size and forecast, by region
    • 5.13.2.Market analysis, by country

CHAPTER 6:CANCER DIAGNOSTICS MARKET, BY END USE

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospital and Clinics
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Diagnostic Laboratories
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Diagnostic Imaging Centers
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country
  • 6.5.Research Institutes
    • 6.5.1.Market size and forecast, by region
    • 6.5.2.Market analysis, by country

CHAPTER 7:CANCER DIAGNOSTICS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.U.S. cancer diagnostics market, by product
      • 7.2.2.1.2.U.S. cancer diagnostics market, by application
      • 7.2.2.1.3.U.S. cancer diagnostics market, by end use
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Canada cancer diagnostics market, by product
      • 7.2.2.2.2.Canada cancer diagnostics market, by application
      • 7.2.2.2.3.Canada cancer diagnostics market, by end use
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Mexico cancer diagnostics market, by product
      • 7.2.2.3.2.Mexico cancer diagnostics market, by application
      • 7.2.2.3.3.Mexico cancer diagnostics market, by end use
    • 7.2.3.North America market size and forecast, by product
    • 7.2.4.North America market size and forecast, by application
    • 7.2.5.North America market size and forecast, by end use
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany cancer diagnostics market, by product
      • 7.3.2.1.2.Germany cancer diagnostics market, by application
      • 7.3.2.1.3.Germany cancer diagnostics market, by end use
      • 7.3.2.2.France
      • 7.3.2.2.1.France cancer diagnostics market, by product
      • 7.3.2.2.2.France cancer diagnostics market, by application
      • 7.3.2.2.3.France cancer diagnostics market, by end use
      • 7.3.2.3.UK
      • 7.3.2.3.1.UK cancer diagnostics market, by product
      • 7.3.2.3.2.UK cancer diagnostics market, by application
      • 7.3.2.3.3.UK cancer diagnostics market, by end use
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy cancer diagnostics market, by product
      • 7.3.2.4.2.Italy cancer diagnostics market, by application
      • 7.3.2.4.3.Italy cancer diagnostics market, by end use
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain cancer diagnostics market, by product
      • 7.3.2.5.2.Spain cancer diagnostics market, by application
      • 7.3.2.5.3.Spain cancer diagnostics market, by end use
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe cancer diagnostics market, by product
      • 7.3.2.6.2.Rest of Europe cancer diagnostics market, by application
      • 7.3.2.6.3.Rest of Europe cancer diagnostics market, by end use
    • 7.3.3.Europe market size and forecast, by product
    • 7.3.4.Europe market size and forecast, by application
    • 7.3.5.Europe market size and forecast, by end use
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
      • 7.4.2.1.Japan
      • 7.4.2.1.1.Japan cancer diagnostics market, by product
      • 7.4.2.1.2.Japan cancer diagnostics market, by application
      • 7.4.2.1.3.Japan cancer diagnostics market, by end use
      • 7.4.2.2.China
      • 7.4.2.2.1.China cancer diagnostics market, by product
      • 7.4.2.2.2.China cancer diagnostics market, by application
      • 7.4.2.2.3.China cancer diagnostics market, by end use
      • 7.4.2.3.Australia
      • 7.4.2.3.1.Australia cancer diagnostics market, by product
      • 7.4.2.3.2.Australia cancer diagnostics market, by application
      • 7.4.2.3.3.Australia cancer diagnostics market, by end use
      • 7.4.2.4.India
      • 7.4.2.4.1.India cancer diagnostics market, by product
      • 7.4.2.4.2.India cancer diagnostics market, by application
      • 7.4.2.4.3.India cancer diagnostics market, by end use
      • 7.4.2.5.South Korea
      • 7.4.2.5.1.South Korea cancer diagnostics market, by product
      • 7.4.2.5.2.South Korea cancer diagnostics market, by application
      • 7.4.2.5.3.South Korea cancer diagnostics market, by end use
      • 7.4.2.6.Rest of Asia-Pacific
      • 7.4.2.6.1.Rest of Asia-Pacific cancer diagnostics market, by product
      • 7.4.2.6.2.Rest of Asia-Pacific cancer diagnostics market, by application
      • 7.4.2.6.3.Rest of Asia-Pacific cancer diagnostics market, by end use
    • 7.4.3.Asia-Pacific market size and forecast, by product
    • 7.4.4.Asia-Pacific market size and forecast, by application
    • 7.4.5.Asia-Pacific market size and forecast, by end use
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
      • 7.5.2.1.Brazil
      • 7.5.2.1.1.Brazil cancer diagnostics market, by product
      • 7.5.2.1.2.Brazil cancer diagnostics market, by application
      • 7.5.2.1.3.Brazil cancer diagnostics market, by end use
      • 7.5.2.2.Saudi Arabia
      • 7.5.2.2.1.Saudi Arabia cancer diagnostics market, by product
      • 7.5.2.2.2.Saudi Arabia cancer diagnostics market, by application
      • 7.5.2.2.3.Saudi Arabia cancer diagnostics market, by end use
      • 7.5.2.3.South Africa
      • 7.5.2.3.1.South Africa cancer diagnostics market, by product
      • 7.5.2.3.2.South Africa cancer diagnostics market, by application
      • 7.5.2.3.3.South Africa cancer diagnostics market, by end use
      • 7.5.2.4.Rest of LAMEA
      • 7.5.2.4.1.Rest of LAMEA cancer diagnostics market, by product
      • 7.5.2.4.2.Rest of LAMEA cancer diagnostics market, by application
      • 7.5.2.4.3.Rest of LAMEA cancer diagnostics market, by end use
    • 7.5.3.LAMEA market size and forecast, by product
    • 7.5.4.LAMEA market size and forecast, by application
    • 7.5.5.LAMEA market size and forecast, by end use

CHAPTER 8:COMPANY PROFILES

  • 8.1.ABBOTT LABORATORIES
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.BECTON, DICKINSON AND COMPANY
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
    • 8.2.6.Key strategic moves and developments
  • 8.3.Bio-Rad Laboratories, Inc.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
    • 8.3.6.Key strategic moves and developments
  • 8.4.Roche Holdings AG (F. Hoffmann-La Roche Ltd.)
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.Danaher Corporation (GE Healthcare)
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.Hologic, Inc.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.KONINKLIJKE PHILIPS N.V. (Philips Healthcare)
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.Qiagen N.V.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.Siemens Healthcare GmbH
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.Thermo Fisher Scientific
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
    • 8.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028 ($MILLION)
  • TABLE 02.CONSUMABLES CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 03.CONSUMABLES CANCER DIAGNOSTICS MARKET, BY TYPE, 2020-2028, ($MILLION)
  • TABLE 04.INSTRUMENTS CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 05.INSTRUMENTS CANCER DIAGNOSTICS MARKET, BY TYPE, 2020-2028, ($MILLION)
  • TABLE 06.GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028 ($MILLION)
  • TABLE 07.BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 08.COLORECTAL CANCER, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 09.CERVICAL CANCER, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 10.LUNG CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 11.PROSTSATE CANCER, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 12.SKIN CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 13.BLOOD CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 14.KIDNEY CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 15.LIVER CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 16.PANCREATIC CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 17.OVARIAN CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 18.OTHERS CANCER CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 19.GLOBAL CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028 ($MILLION)
  • TABLE 20.HOSPITALS AND CLINICS, CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 21.DIAGNOSTICS LABORATORIES CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 22.DIAGNOSTICS IMAGING CENTERS CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 23.RESEARCH INSTITUTES CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 24.CANCER DIAGNOSTICS MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 25.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 26.U.S. CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 27.U.S. CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 28.U.S. CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 29.CANADA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 30.CANADA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 31.CANADA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 32.MEXICO CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 33.MEXICO CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 34.MEXICO CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 35.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 36.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 37.NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 38.EUROPE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 39.GERMANY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 40.GERMANY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 41.GERMANY CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 42.FRANCE CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 43.FRANCE CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 44.FRANCE CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 45.UK CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 46.UK CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 47.UK CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 48.ITALY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 49.ITALY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 50.ITALY CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 51.SPAIN CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 52.SPAIN CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 53.SPAIN CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 54.REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 55.REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 56.REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 57.EUROPE CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 58.EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 59.EUROPE CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 60.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 61.JAPAN CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 62.JAPAN CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 63.JAPAN CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 64.CHINA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 65.CHINA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 66.CHINA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 67.AUSTRALIA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 68.AUSTRALIA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 69.AUSTRALIA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 70.INDIA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 71.INDIA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 72.INDIA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 73.SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 74.SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 75.SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 76.REST OF ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 77.REST OF ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 78.REST OF ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 79.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 80.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 81.ASIA-PACIFIC CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 82.LAMEA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 83.LAMEA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020-2028 (UNITS)
  • TABLE 84.BRAZIL CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 85.BRAZIL CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 86.BRAZIL CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 87.SAUDI ARABIA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 88.SAUDI ARABIA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 89.SAUDI ARABIA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 90.SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 91.SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 92.SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 93.REST OF LAMEA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 94.REST OF LAMEA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 95.REST OF LAMEA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 96.LAMEA CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2020-2028
  • TABLE 97.LAMEA CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2020-2028
  • TABLE 98.LAMEA CANCER DIAGNOSTICS MARKET, BY END USE, 2020-2028
  • TABLE 99.ABBOTT: COMPANY SNAPSHOT
  • TABLE 100.ABBOTT: OPERATING SEGMENT
  • TABLE 101.ABBOTT LABORATORIES PLC: PRODUCT PORTFOLIO
  • TABLE 102.BD: SNAPSHOT
  • TABLE 103.BD: OPERATING SEGMENTS
  • TABLE 104.BD: PRODUCT PORTFOLIO
  • TABLE 105.BD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106.BIO-RAD: COMPANY SNAPSHOT
  • TABLE 107.MYRIAD: OERATING SEGMENT
  • TABLE 108.BIO-RAD: PRODUCT PORTFOLIO
  • TABLE 109.BIO-RAD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110.ROCHE: COMPANY SNAPSHOT
  • TABLE 111.ROCHE: OPERATING SEGMENTS
  • TABLE 112.ROCHE: PRODUCT PORTFOLIO
  • TABLE 113.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114.DANAHER: COMPANY SNAPSHOT
  • TABLE 115.DANAHER: OPERATING SEGMENT
  • TABLE 116.DANAHER: PRODUCT PORTFOLIO
  • TABLE 117.DANAHER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118.HOLOGIC: COMPANY SNAPSHOT
  • TABLE 119.HOLOGIC: OERATING SEGMENT
  • TABLE 120.HOLOGIC: PRODUCT PORTFOLIO
  • TABLE 121.HOLOGIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122.PHILIPS: COMPANY SNAPSHOT
  • TABLE 123.PHILIPS: OERATING SEGMENT
  • TABLE 124.PHILIPS: PRODUCT PORTFOLIO
  • TABLE 125.PHILIPS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126.QIAGEN: COMPANY SNAPSHOT
  • TABLE 127.QIAGEN: PRODUCT PORTFOLIO
  • TABLE 128.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 129.SIEMENS: COMPANY SNAPSHOT
  • TABLE 130.SIEMENS: OERATING SEGMENTS
  • TABLE 131.SIEMENS: PRODUCT PORTFOLIO
  • TABLE 132.SIEMENS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 133.THERMO: COMPANY SNAPSHOT
  • TABLE 134.THERMO: OPERATING SEGMENTS
  • TABLE 135.THERMO: PRODUCT PORTFOLIO
  • TABLE 136.THERMO: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01.GLOBAL CANCER DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
  • FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE COMPETITIVE RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2019
  • FIGURE 12.PIE CHART FOR CANCER CASES DIAGNOSED IN 2020
  • FIGURE 13.COMPARATIVE ANALYSIS OF CONSUMABLES CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 14.ANTIBODIES MARKET, 2020-2028, ($MILLION)
  • FIGURE 15.KITS & REAGENTS MARKET, 2020-2028, ($MILLION)
  • FIGURE 16.KITS & REAGENTS MARKET, 2020-2028, ($MILLION)
  • FIGURE 17.KITS & REAGENTS MARKET, 2020-2028, ($MILLION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF INSTRUMENTS CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 19.PATHOLOGY-BASED INSTRUMENTS MARKET, 2020-2028, ($MILLION)
  • FIGURE 20.IMAGING INSTRUMENTS MARKET, 2020-2028, ($MILLION)
  • FIGURE 21.BIOPSY INSTRUMENTS MARKET, 2020-2028, ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF COLORECTAL CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 24.COMPARATIVE ANALYSIS OF CERVICAL CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 25.COMPARATIVE ANALYSIS OF LUNG CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 26.COMPARATIVE ANALYSIS OF PROSTATE CANCER, CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 27.COMPARATIVE ANALYSIS OF SKIN CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 28.COMPARATIVE ANALYSIS OF BLOOD CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 29.COMPARATIVE ANALYSIS OF KIDNEY CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 30.COMPARATIVE ANALYSIS OF LIVER CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 31.COMPARATIVE ANALYSIS OF PANCREATIC CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 32.COMPARATIVE ANALYSIS OF OVARIAN CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 33.COMPARATIVE ANALYSIS OF OTHERS CANCER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 34.COMPARATIVE ANALYSIS OF RETAIL PHARMACIES CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 35.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 36.COMPARATIVE ANALYSIS OF E-COMMERCE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 37.COMPARATIVE ANALYSIS OF E-COMMERCE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 38.ABBOTT: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 39.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 40.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 41.BD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 42.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 43.BD: REVENUE SHARE, BY REGION, 2020 (%)
  • FIGURE 44.BIO-RAD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 45.BIO-RAD: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 46.BIO-RAD: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 47.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 48.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 ($MILLION)
  • FIGURE 49.DANAHER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 50.DANAHER: REVENUE SHARE BY SEGMENT, 2020
  • FIGURE 51.DANAHER: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 52.HOLOGIC: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 53.HOLOGIC: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 54.HOLOGIC: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 55.PHILIPS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 56.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 57.PHILIPS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 58.QIAGEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 59.QIAGEN: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 60.SIEMENS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 61.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 62.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 63.THERMO: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 64.THERMO: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • FIGURE 65.THERMO: REVENUE SHARE, BY REGION, 2020 (%)